Maze Therapeutics (MAZE) EPS (Weighted Average and Diluted) (2024 - 2026)
Maze Therapeutics' (MAZE) quarterly EPS (Weighted Average and Diluted) came in at -$0.45 in Q1 2026, up 60.87% year-on-year from -$0.28 in Q1 2025, and up 25.0% quarter-over-quarter from -$0.6 in Q4 2025.
Maze Therapeutics (MAZE) EPS (Weighted Average and Diluted) (2024 - 2026) Analysis & Trends
Maze Therapeutics has disclosed EPS (Weighted Average and Diluted) across 3 years of filings, most recently posting -$0.45 for Q1 2026.
- EPS (Weighted Average and Diluted) for Q1 2026 came in at -$0.45, up 60.87% year-over-year; the trailing twelve-month figure through Mar 2026 was -$2.48 (up 74.17% YoY), and the FY2025 annual result was -$3.05, down 344.0% from the prior year.
- EPS (Weighted Average and Diluted) came in at -$0.45 for Q1 2026 at Maze Therapeutics, up from -$0.6 in the prior quarter.
- In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $3.22 in Q2 2024 to a low of -$13.91 in Q1 2024.
- The 3-year median for EPS (Weighted Average and Diluted) is -$0.77 (2025), against an average of -$2.89.
- Peak annual rise in EPS (Weighted Average and Diluted) reached 93.56% in 2025, while the deepest fall reached 123.91% in 2025.
- Maze Therapeutics' EPS (Weighted Average and Diluted) stood at -$1.42 in 2024, then surged by 57.75% to -$0.6 in 2025, then climbed by 25.0% to -$0.45 in 2026.
- The last three EPS (Weighted Average and Diluted) figures came in at -$0.45 (Q1 2026), -$0.6 (Q4 2025), and -$0.66 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Weighted Avg. Diluted) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | 0.68 |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 3.06 |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 3,086.42 |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 0.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 0.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 4.02 |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -0.61 |
| 10 | Maze Therapeutics | 1.39 Bn | 1.39 Bn | 18.21 Mn | -0.45 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -0.45 |
| Dec 31, 2025 | -0.60 |
| Sep 30, 2025 | -0.66 |
| Jun 30, 2025 | -0.77 |
| Mar 31, 2025 | -1.15 |
| Dec 31, 2024 | -1.42 |
| Sep 30, 2024 | -10.25 |
| Jun 30, 2024 | 3.22 |
| Mar 31, 2024 | -13.91 |